Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct SARS-CoV-2 lineage, the BA.2.86 variant, also emerged. BA.2.86 is phylogenetically distinct from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Additionally, four clinically available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 are significantly lower than those of BA.2 both in vitro and in vivo, the attenuated pathogenicity of BA.2.86 is likely due to its decreased replication capacity. These findings uncover the features of BA.2.86, providing insights for control and treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Cell host & microbe - 32(2024), 2 vom: 14. Feb., Seite 170-180.e12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tamura, Tomokazu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amino Acids |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.chom.2024.01.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367707934 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367707934 | ||
| 003 | DE-627 | ||
| 005 | 20240219232022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240128s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.chom.2024.01.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM367707934 | ||
| 035 | |a (NLM)38280382 | ||
| 035 | |a (PII)S1931-3128(24)00005-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tamura, Tomokazu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Virological characteristics of the SARS-CoV-2 BA.2.86 variant |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct SARS-CoV-2 lineage, the BA.2.86 variant, also emerged. BA.2.86 is phylogenetically distinct from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Additionally, four clinically available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 are significantly lower than those of BA.2 both in vitro and in vivo, the attenuated pathogenicity of BA.2.86 is likely due to its decreased replication capacity. These findings uncover the features of BA.2.86, providing insights for control and treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BA.2.86 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a pathogenicity | |
| 650 | 7 | |a Amino Acids |2 NLM | |
| 700 | 1 | |a Mizuma, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Nasser, Hesham |e verfasserin |4 aut | |
| 700 | 1 | |a Deguchi, Sayaka |e verfasserin |4 aut | |
| 700 | 1 | |a Padilla-Blanco, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Oda, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Uriu, Keiya |e verfasserin |4 aut | |
| 700 | 1 | |a Tolentino, Jarel E M |e verfasserin |4 aut | |
| 700 | 1 | |a Tsujino, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Rigel |e verfasserin |4 aut | |
| 700 | 1 | |a Kojima, Isshu |e verfasserin |4 aut | |
| 700 | 1 | |a Nao, Naganori |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuda, Masumi |e verfasserin |4 aut | |
| 700 | 1 | |a Jonathan, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kosugi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Ziyi |e verfasserin |4 aut | |
| 700 | 1 | |a Hinay, Alfredo A |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Putri, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yoonjin |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yuri L |e verfasserin |4 aut | |
| 700 | 1 | |a Asakura, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nagashima, Mami |e verfasserin |4 aut | |
| 700 | 1 | |a Sadamasu, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimura, Kazuhisa |e verfasserin |4 aut | |
| 700 | 0 | |a Genotype to Phenotype Japan (G2P-Japan) Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Akatsuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Jumpei |e verfasserin |4 aut | |
| 700 | 1 | |a Irie, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Zahradnik, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Terumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Takayama, Kazuo |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuno, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuhara, Takasuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Kei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell host & microbe |d 2007 |g 32(2024), 2 vom: 14. Feb., Seite 170-180.e12 |w (DE-627)NLM172227933 |x 1934-6069 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:2 |g day:14 |g month:02 |g pages:170-180.e12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.chom.2024.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 2 |b 14 |c 02 |h 170-180.e12 | ||